Cargando…

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria

Cerebral malaria is a severe complication of Plasmodium falciparum infection associated with high mortality even when highly effective antiparasitic therapy is used. Adjunctive therapies that modify the pathophysiological processes caused by malaria are a possible way to improve outcome. This review...

Descripción completa

Detalles Bibliográficos
Autor principal:	Serghides, Lena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135089/ https://www.ncbi.nlm.nih.gov/pubmed/21772838 http://dx.doi.org/10.1155/2012/513865

Ejemplares similares

PPARγ Agonists Improve Survival and Neurocognitive Outcomes in Experimental Cerebral Malaria and Induce Neuroprotective Pathways in Human Malaria
por: Serghides, Lena, et al.
Publicado: (2014)

Adjunctive therapy for severe malaria: a review and critical appraisal
por: Varo, Rosauro, et al.
Publicado: (2018)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Modulation of cerebral malaria by curcumin as an adjunctive therapy
por: Jain, Kunal, et al.
Publicado: (2013)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Pentoxifylline as an adjunct therapy in children with cerebral malaria
por: Lell, Bertrand, et al.
Publicado: (2010)

Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria
por: Varo, Rosauro, et al.
Publicado: (2017)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Regulation of Glial Cell Functions by PPAR-γ Natural and Synthetic Agonists
por: Bernardo, Antonietta, et al.
Publicado: (2008)

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
por: Veliceasa, Dorina, et al.
Publicado: (2008)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
por: Ballav, Sangeeta, et al.
Publicado: (2022)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer
por: Belfiore, A., et al.
Publicado: (2009)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Do we know enough to find an adjunctive therapy for cerebral malaria in African children?
por: Riggle, Brittany A., et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
por: Ayza, Muluken Altaye, et al.
Publicado: (2020)

Aptamer Technology: Adjunct Therapy for Malaria
por: Nik Kamarudin, Nik Abdul Aziz, et al.
Publicado: (2017)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Anticancer Role of PPARγ Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes
por: Simpson-Haidaris, P. J., et al.
Publicado: (2010)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

The plant-based immunomodulator curcumin as a potential candidate for the development of an adjunctive therapy for cerebral malaria
por: Mimche, Patrice N, et al.
Publicado: (2011)

A Role for the PPARγ in Cancer Therapy
por: Campbell, Moray J., et al.
Publicado: (2008)

Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013)

Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes
por: Piątkowska-Chmiel, Iwona, et al.
Publicado: (2022)

Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist
por: Goto, Tsuyoshi, et al.
Publicado: (2011)

Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts
por: Koo, Jun Bon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5js83gme5u5bibt1oacfls85rl